CD8A and neoplasm: Although it was previously reported that the activation of TLR-3 with rintatolimod enhances the maturation of DCs which could result in more activated (CD4+ and CD8+) T cells that establish anti-tumor immunity [17,38], we did not find significantly increased circulating DC or T-cell counts after six weeks of treatment with rintatolimod.